Federal Register Notice: FDA’s Anesthetic and Analgesic Drug Products Advisory Committee will meet 4/22, from 8 a.m. to 5 p.m. at the FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD. The committee will discuss the safety and efficacy for a QRxPharma Inc. NDA for Moxduo (morphine sulfate and oxycodone hydrochloride) capsules for the proposed indication of managing moderate to severe acute pain where the use of an opioid analgesic is appropriate. This product represents the first drug combination consisting of two immediate-release opioids. Contact Caleb Briggs, (301) 796-9001. To view this notice, click here.